Clinical Trial Update: Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of selumetinib for relapsed or refractory diffuse large B-cell lymphoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2016-02-03